HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation.

AbstractBACKGROUND:
Extracorporeal photopheresis (ECP) has been used to treat acute and chronic rejection after solid organ transplantation. However, data supporting the use of ECP for bronchiolitis obliterans syndrome (BOS) after lung transplantation are limited.
METHODS:
We retrospectively analyzed the efficacy and safety of ECP for progressive BOS at our institution. Between January 1, 2000, and December 31, 2007, 60 lung allograft recipients were treated with ECP for progressive BOS.
RESULTS:
During the 6-month period before the initiation of ECP, the average rate of decline in forced expiratory volume in 1 second (FEV(1)) was -116.0 ml/month, but the slope decreased to -28.9 ml/month during the 6-month period after the initiation of ECP, and the mean difference in the rate of decline was 87.1 ml/month (95% confidence interval, 57.3-116.9; p < 0.0001). The FEV(1) improved in 25.0% of patients after the initiation of ECP, with a mean increase of 20.1 ml/month.
CONCLUSIONS:
ECP is associated with a reduction in the rate of decline in lung function associated with progressive BOS.
AuthorsMatthew R Morrell, George J Despotis, Douglas M Lublin, George A Patterson, Elbert P Trulock, Ramsey R Hachem
JournalThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (J Heart Lung Transplant) Vol. 29 Issue 4 Pg. 424-31 (Apr 2010) ISSN: 1557-3117 [Electronic] United States
PMID19853479 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Immunosuppressive Agents
  • Azithromycin
Topics
  • Adult
  • Aged
  • Anti-Bacterial Agents (therapeutic use)
  • Azithromycin (therapeutic use)
  • Bronchiolitis Obliterans (etiology, therapy)
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Forced Expiratory Volume (physiology)
  • Graft Rejection (complications)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Kaplan-Meier Estimate
  • Lung (physiopathology)
  • Lung Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Photopheresis (adverse effects)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: